Alarasan Arun Kumar, Agrawal Jitendre, Choudhary Bhanu, Melhotra Amrita, Uike Satyendre, Mukherji Arghya
Department of Anaesthesiology, Chettinad Academy of Research and Education, Kanchipuram, Tamil Nadu, India.
Department of Anaesthesiology, Gajra Raja Medical College, Gwalior, Madhya Pradesh, India.
J Anaesthesiol Clin Pharmacol. 2016 Apr-Jun;32(2):234-9. doi: 10.4103/0970-9185.182108.
With the use of ultrasound, a minimal effective volume of 20 ml has been described for supraclavicular brachial plexus block. However achieving a long duration of analgesia with this minimal volume remains a challenge. We aimed to determine the effect of dexamethasone on onset and duration of analgesia in low volume supraclavicular brachial plexus block.
Sixty patients were randomly divided into two groups of 30 each. Group C received saline (2 ml) + 20 ml of 0.5% bupivacaine and Group D received dexamethasone (8 mg) + 20 ml of 0.5% bupivacaine in supraclavicular brachial plexus block. Hemodynamic variables and visual analog scale (VAS) score were noted at regular intervals until 450 min. The onset and duration of sensory and motor block were measured. The incidence of "Halo" around brachial plexus was observed. Student's t-test and Chi-square test were used for statistical analysis.
The onset of sensory and motor block was significantly earlier in dexamethasone group (10.36 ± 1.99 and 12 ± 1.64) minutes compared to control group (12.9 ± 2.23 and 18.03 ± 2.41) minutes. The duration of sensory and motor block was significantly prolonged in dexamethasone group (366 ± 28.11 and 337.33 ± 28.75) minutes compared to control group (242.66 ± 26.38 and 213 ± 26.80) minutes. The VAS score was significantly lower in dexamethasone group after 210 min. "Halo" was present around the brachial plexus in all patients in both the groups.
Dexamethasone addition significantly increases the duration of analgesia in patients receiving low volume supraclavicular brachial plexus block. No significant side-effects were seen in patients receiving dexamethasone as an adjunct.
使用超声技术时,已报道锁骨上臂丛神经阻滞的最小有效容量为20毫升。然而,用此最小容量实现长时间镇痛仍是一项挑战。我们旨在确定地塞米松对低容量锁骨上臂丛神经阻滞镇痛起效时间和持续时间的影响。
60例患者随机分为两组,每组30例。C组在锁骨上臂丛神经阻滞中接受生理盐水(2毫升)+20毫升0.5%布比卡因,D组接受地塞米松(8毫克)+20毫升0.5%布比卡因。定期记录血流动力学变量和视觉模拟评分(VAS),直至450分钟。测量感觉和运动阻滞的起效时间和持续时间。观察臂丛神经周围“晕圈”的发生率。采用学生t检验和卡方检验进行统计分析。
与对照组(12.9±2.23和18.03±2.41分钟)相比,地塞米松组感觉和运动阻滞的起效时间显著更早(10.36±1.99和12±1.64分钟)。与对照组(242.66±26.38和213±26.80分钟)相比,地塞米松组感觉和运动阻滞的持续时间显著延长(366±28.11和337.33±28.75分钟)。210分钟后,地塞米松组的VAS评分显著更低。两组所有患者的臂丛神经周围均出现“晕圈”。
添加地塞米松可显著延长接受低容量锁骨上臂丛神经阻滞患者的镇痛持续时间。接受地塞米松作为辅助用药的患者未出现明显副作用。